UBS Group’s Biolase, Inc. BIOL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-5,615
| Closed | -$6.3K | – | 10278 |
|
|
2023
Q4 | $6.3K | Buy |
+5,615
| New | +$8.02K | ﹤0.01% | 7712 |
|
|
2023
Q3 | – | Sell |
-407
| Closed | -$2.89K | – | 10152 |
|
|
2023
Q2 | $2.89K | Buy |
407
+371
| +1,031% | +$6.21K | ﹤0.01% | 7680 |
|
|
2023
Q1 | $1.01K | Buy |
36
+19
| +112% | +$925 | ﹤0.01% | 8846 |
|
|
2022
Q4 | $1.13K | Sell |
17
-39
| -70% | -$5.61K | ﹤0.01% | 9949 |
|
|
2022
Q3 | $14K | Buy |
56
+51
| +1,020% | +$20.4K | ﹤0.01% | 7952 |
|
|
2022
Q2 | $2K | Buy |
+5
| New | +$2.75K | ﹤0.01% | 9661 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 11119 |
|
|
2021
Q4 | – | Sell |
-2
| Closed | -$2.52K | – | 10888 |
|
|
2021
Q3 | $4K | Sell |
2
-5
| -71% | -$8.16K | ﹤0.01% | 8709 |
|
|
2021
Q2 | $13K | Hold |
7
| – | – | ﹤0.01% | 7816 |
|
|
2021
Q1 | $14K | Buy |
+7
| New | +$17.2K | ﹤0.01% | 7687 |
|
|
2020
Q4 | – | Sell |
-18
| Closed | -$13.7K | – | 8872 |
|
|
2020
Q3 | $13K | Buy |
18
+11
| +157% | +$10.3K | ﹤0.01% | 6659 |
|
|
2020
Q2 | $8K | Buy |
7
+3
| +75% | +$3.42K | ﹤0.01% | 7163 |
|
|
2020
Q1 | $4K | Buy |
+4
| New | +$6.21K | ﹤0.01% | 7425 |
|
|
2019
Q4 | – | Sell |
-4
| Closed | -$6.15K | – | 8490 |
|
|
2019
Q3 | $8K | Hold |
4
| – | – | ﹤0.01% | 7298 |
|
|
2019
Q2 | $14K | Hold |
4
| – | – | ﹤0.01% | 6862 |
|
|
2019
Q1 | $25K | Buy |
4
+2
| +100% | +$9.71K | ﹤0.01% | 6113 |
|
|
2018
Q4 | $4K | Hold |
2
| – | – | ﹤0.01% | 7653 |
|
|
2018
Q3 | $9K | Sell |
2
-2
| -50% | -$8K | ﹤0.01% | 7224 |
|
|
2018
Q2 | $13K | Hold |
4
| – | – | ﹤0.01% | 7003 |
|
|
2018
Q1 | $18K | Buy |
4
+2
| +100% | +$11.2K | ﹤0.01% | 6480 |
|
|
2017
Q4 | $10K | Sell |
2
-2
| -50% | -$14.1K | ﹤0.01% | 7038 |
|
|
2017
Q3 | $28K | Buy |
4
+2
| +100% | +$17.2K | ﹤0.01% | 6217 |
|
|
2017
Q2 | $30K | Buy |
2
+1
| +100% | +$14.8K | ﹤0.01% | 6022 |
|
|
2017
Q1 | $19K | Sell |
1
-1
| -50% | -$18.1K | ﹤0.01% | 6181 |
|
|
2016
Q4 | $31K | Buy |
2
+1
| +100% | +$19.8K | ﹤0.01% | 6215 |
|
|
2016
Q3 | $27K | Hold |
1
| – | – | ﹤0.01% | 6040 |
|
|
2016
Q2 | $15K | Hold |
1
| – | – | ﹤0.01% | 6526 |
|
|
2016
Q1 | $12K | Hold |
1
| – | – | ﹤0.01% | 6549 |
|
|
2015
Q4 | $11K | Buy |
+1
| New | +$10.9K | ﹤0.01% | 7245 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 7972 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7892 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 7931 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 8620 |
|
Other funds holding BIOL
VF
HF
XT
KWA
UBS Group's BIOL Position: Q1 2024 in Review
UBS Group sold out of Biolase, Inc. (BIOL) in Q1 2024, closing a stake of 5,615 shares — an estimated $6.3K sold.
UBS Group first reported a position in BIOL in Q4 2015 and held it in 28 quarters. The position peaked at $31K in Q4 2016. 18 funds tracked by Wall St. Rank hold BIOL as of Q1 2024.
- UBS Group reported no remaining Biolase, Inc. position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 5,615 Biolase, Inc. shares in Q1 2024, an estimated $6.3K.
- UBS Group first reported a position in Biolase, Inc. in Q4 2015 and held it in 28 quarters.
- UBS Group's Biolase, Inc. position peaked at $31K in Q4 2016.
- 18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.